Innohep

Innohep

tinzaparin

Manufacturer:

LEO Pharma

Distributor:

DKSH
Concise Prescribing Info
Contents
Tinzaparin Na
Indications/Uses
Treatment of DVT & pulmonary embolism (PE). Prevention of post-op DVT in patients undergoing general & orthopaedic surgery; of clotting in in-dwelling IV lines for extracorporeal circulation & haemodialysis.
Dosage/Direction for Use
Treatment of DVT & PE 175 anti-Xa IU/kg SC once daily. Thromboprophylaxis in patients w/ moderate risk of thrombosis (general surgery) 3,500 anti-Xa IU SC 2 hr before surgery & 3,500 anti-Xa IU once daily for 7-10 days post-op. Thromboprophylaxis in patients w/ high risk of thrombosis (eg, total hip replacement) 4,500 anti-Xa IU SC 12 hr before surgery, or 50 anti-Xa IU/kg SC 2 hr before surgery & then once daily until the patient has been mobilized. Short-term haemodialysis (<4 hr) Bolus dose of 2,000-2,500 anti-Xa IU into the arterial side of the dialyser (or IV) at the beginning of dialysis. Long-term haemodialysis (>4 hr) Bolus dose of 2,500 anti-Xa IU into the arterial side of the dialyser (or IV) at the beginning of dialysis, followed by an infusion of 750 anti-Xa IU/hr. If required, increase or decrease bolus dose in steps of 250-500 anti-Xa IU until satisfactory response is obtained.
Contraindications
Hypersensitivity. Generalized or local haemorrhagic tendency. Uncontrolled severe HTN. Acute cerebral insults. Septic endocarditis. 20,000 anti-Xa IU/mL Contains Na metabisulphite; may cause allergic reactions, including anaphylaxis in predisposed patients. Vial Contains benzyl alcohol. Do not give to premature babies & neonates due to risk of gasping syndrome.
Special Precautions
Do not administer by IM inj due to risk of local haematoma formation. Closely monitor for signs or symptoms of neurological injury in patients receiving concurrent spinal or epidural anaesth. Patients w/ hepatic impairment; severe renal impairment; elderly w/ renal impairment. Assess renal function. Consider monitoring of anti-factor Xa activity in patients w/ severe renal impairment (CrCl <30 mL/min). Not recommended in pregnant women w/ prosthetic heart valves. Pregnancy & lactation.
Adverse Reactions
Priapism & skin necrosis (few cases only).
Drug Interactions
Enhanced anticoagulant effect w/ other drugs affecting haemostasis eg, vit K antagonists & dextran.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AB10 - tinzaparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.
Presentation/Packing
Form
Innohep inj 10000 AXa iu/mL
Packing/Price
(Vial) 2 mL x 10 × 1's
Form
Innohep inj 20000 AXa iu/mL
Packing/Price
(Vial) 2 mL x 10 × 1's
Form
Innohep pre-filled inj 10000 AXa iu/mL
Packing/Price
(Syringe) 0.35 mL x 10 × 1's; (Syringe) 0.45 mL x 10 × 1's
Form
Innohep pre-filled inj 20000 AXa iu/mL
Packing/Price
(Syringe) 0.5 mL x 2 × 1's; (Syringe) 0.7 mL x 2 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in